Clearmind Medicine and SciSparc Collaboration Yields Another Patent Application for Cocaine Addiction Treatment

Author: Charles Gross | June 02, 2022 07:53am
Clearmind Medicine Inc. (CSE:CMND, OTC:CMNDF, FSE: CWY0)) ("Clearmind" or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced it has filed a provisional patent application related to cocaine addiction.The move results from the company's recently launched collaboration with SciSparc Ltd. (NASDAQ:SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system ("SciSparc"). The patent application refers to the proprietary combination of Clearmind's MEAI, a novel proprietary psychedelic treatment for addiction, with SciSparc's CannAmide™. The two companies plan to pursue a pre-clinical trial to examine the effect of the combination treatment as an anti-reward agent for treating cocaine addiction. Cocaine addiction in the United States peaked in the 1990s, and the current estimates by the National Institute on Drug Abuse claim at least 1.3 million Americans are addicted to cocaine. Annually, these users go to the hospital more than 350,000 times and account for 54% of drug-related incarcerations in federal jails and prisons, according to recent statistics from the U. S. Department of Justice. In addition, cocaine is either suspected or confirmed as the cause for nearly 16,000 overdose deaths in the United States each year. It's at least a contributing factor in many more deaths, usually from violence, associated medical conditions or other health impacts of the user's lifestyle. "Clearmind's main focus is substance abuse and binge behaviors," said Dr. Adi Zuloff- Shani, Clearmind's Chief Executive Officer. Dr. Adi Zuloff- Shani  continued, "Since the successful initial results demonstrated potential treatment for cocaine abuse, we intend to expand the collaboration with SciSparc and explore the effect of our combination treatment for cocaine. Although cocaine addiction is an established epidemic worldwide, it has no dedicated treatment in the market, which makes our candidate treatment highly attractive."

Posted In: CMNDF CSE:CMND SPRC